Antibacterial Spectrum of a Novel Des-Fluoro(6) Quinolone, BMS-284756

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2000-12-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1128/aac.44.12.3351-3356.2000PMID 11083639PMCID PMC90204
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin.

  2000cited by this paper
• Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard

  2000cited by this paper
• Correlation of Oxacillin MIC with mecAGene Carriage in Coagulase-Negative Staphylococci

  2000cited by this paper
• In Vitro and In Vivo Antimicrobial Activities of T-3811ME, a Novel Des-F(6)-Quinolone

  1999cited by this paper
• Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials.

  1998influential reference
• Mathematical Examination of Dual Individualization Principles (I): Relationships between AUC above MIC and Area under the Inhibitory Curve for Cefmenoxime, Ciprofloxacin, and Tobramycin

  1991cited by this paper
• Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically

  1990cited by this paper
• Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital

  1990cited by this paper
• CIPROFLOXACIN RESISTANCE IN EPIDEMIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS

  1988cited by this paper
• Ciprofloxacin resistance in epidemic methicillin-resistant Staphylococcus aureus.

  1988cited by this paper
• National Committee for Clinical Laboratory Standards.

  1980cited by this paper

• New Pharmacokinetic and Microbiological Prediction Equations to Be Used as Models for the Search of Antibacterial Drugs

  2022cites this paper
• Effectiveness of antibacterial agents against cell-invading bacteria such as Streptococcus pyogenes and Haemophilus influenzae

  2021cites this paper
• Garenoxacin is effective against bacteria invading cells such as Streptococcus pyogenes and Haemophilus influenzae

  2021cites this paper
• Comparison of in vivo activity of garenoxacin and levofloxacin in a murine pneumonia mixed-infection model by Streptococcus pneumoniae and Parvimonas micra.

  2019cites this paper
• Difluoromethylation of Phenols and Thiophenols with S-(Difluoromethyl)sulfonium Salt: Reaction, Scope and Mechanistic Study.

  2019cites this paper
• Effective therapeutic regimens in two South Asian countries with high resistance to major Helicobacter pylori antibiotics

  2019cites this paper
• Transferable Mechanisms of Quinolone Resistance from 1998 Onward

  2019cites this paper
• Beneficial Effect of Early Intervention with Garenoxacin for Bacterial Infection-Induced Acute Exacerbation of Bronchial Asthma and Chronic Obstructive Pulmonary Disease

  2019cites this paper
• 4-Quinolone Derivatives and Their Activities Against Gram-negative Pathogens

  2018cites this paper
• Recent developments of quinolone-based derivatives and their activities against Escherichia coli.

  2018cites this paper
• In vitro activity of various antibiotics against clinical strains of Legionella species isolated in Japan.

  2018cites this paper
• Effectiveness and safety of the pre-prescription of garenoxacin in comparison to moxifloxacin for low-risk febrile neutropenia in breast cancer patients undergoing adjuvant and neoadjuvant chemotherapy

  2018cites this paper
• 4-Quinolone derivatives and their activities against Gram positive pathogens.

  2018cites this paper
• Investigation for the mechanism of quinolone antibacterial agent ofloxacin-induced chondrotoxicity in juvenile rats [an abstract of dissertation and a summary of dissertation review]. 論文内容の要旨

  2018cites this paper
• Advance Publication by J-STAGE Japanese Journal of Infectious Diseases

  2017cites this paper
• Garenoxacin pharmacokinetics in patients undergoing maintenance hemodialysis

  2017cites this paper
• Comparison of levofloxacin and garenoxacin for antibacterial prophylaxis during neutropenia

  2017cites this paper
• An Optimal Approach for Fluoroquinolone Garenoxacin Prophylaxis in Patients with Hematological Malignancies and Chemotherapy-induced Neutropenia

  2017cites this paper
• Molecular dynamics simulations of molecularly imprinted polymer approaches to the preparation of selective materials to remove norfloxacin

  2016cites this paper
• Clinical utility of Garenoxacin in Lower Respiratory Tract Infections: A Retrospective Analyzes: A Case-Cohort Study

  2016cites this paper
• A Case-Cohort Study on Clinical utility of Garenoxacin mesylate in Respiratory Tract Infections: A Retrospective Analyses

  2015cites this paper
• Pharmacokinetic study of garenoxacin in severe renal failure patients.

  2015cites this paper
• Comparison of garenoxacin with levofloxacin as antimicrobial prophylaxis in acute myeloid leukemia.

  2015cites this paper
• A Case Cohort Study on Clinical Utility of Garenoxacin Mesylate in Typhoid: Retrospective

  2015cites this paper
• Dual targeting DNA gyrase B (GyrB) and topoisomerse IV (ParE) inhibitors: A review.

  2015cites this paper
• A prescription event monitoring study on the utility of garenoxacin, a newer fluoroquinolone in India

  2015cites this paper
• Garenoxacin in Skin and Skin Structure Infections Sustained due to Road Traffic Accident.

  2014influential citation
• Effect of moxifloxacin on survival, lipid peroxidation and inflammation in immunosuppressed rats with soft tissue infection caused by Stenotrophomonas maltophilia

  2014cites this paper
• GARENOXACIN IN SKIN & SKIN STRUCTURE INFECTIONS COMPLICATED BY BEAR BITE

  2014cites this paper
• Garenoxacin in difficult to treat lung abscess – A case study report

  2014cites this paper
• Garenoxacin in the treatment of community-acquired pneumonia -

  2014cites this paper
• Synthesis and Anti Bacterial and Anti-ulcer Evaluation of New S-mannich Bases of 4,6-diaryl-3,4-dihydropyrimidin-2(1H)-thiones

  2013cites this paper
• Evaluation of fluoroquinolone reduced dosage regimens in elderly patients by using pharmacokinetic modelling and Monte Carlo simulations.

  2012cites this paper
• Guide to Selection of Fluoroquinolones in Patients with Lower Respiratory Tract Infections

  2012cites this paper
• Vitreous and Aqueous Penetration of Orally and Topically Administered Moxifloxacin

  2011cites this paper
• Optimal dose finding of garenoxacin based on population pharmacokinetics/pharmacodynamics and Monte Carlo simulation

  2011influential citation
• New quinolone antibiotics: a survey of the literature from 2005 to 2010

  2010cites this paper
• Efficacy and Safety of Garenoxacin versus Moxifloxacin in Acute Exacerbation of COPD: A Comparative Study

  2010cites this paper
• Susceptibility and bactericidal activity of 8 oral quinolones against conventional-fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates.

  2009cites this paper
• New antimicrobials on the horizon

  2009cites this paper
• Sitafloxacin Activity against Helicobacter pylori Isolates, Including Those with gyrA Mutations

  2009influential citation
• Effect of cefuroxime and moxifloxacin on Staphylococcus epidermidis adherence to intraocular lenses.

  2009cites this paper
• Calculation of AQCmax: comparison of five ophthalmic fluoroquinolone solutions*

  2008cites this paper
• Calculation of AQCmax: comparison of five ophthalmic fluoroquinolone solutions*.

  2008cites this paper
• Clinical studies of garenoxacin.

  2008cites this paper
• Safety assessment of biopharmaceuticals: Japanese perspective on ICH S6 guideline maintenance.

  2008cites this paper
• Synthesis and structure-activity relationship of 7-(substituted)-aminomethyl-4-quinolone-3-carboxylic acid derivatives.

  2007cites this paper
• In vitro activity of garenoxacin tested against a worldwide collection of ciprofloxacin-susceptible and ciprofloxacin-resistant Enterobacteriaceae strains (1999-2004).

  2007cites this paper
• Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.

  2007cites this paper
• Symposium section Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae

  2007cites this paper
• Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.

  2007cites this paper
• Penetration of garenoxacin into lung tissues and bone in subjects undergoing lung biopsy or resection*

  2007cites this paper
• Laser-induced fluorescence-capillary electrophoresis and fluorescence microplate reader measurement: two methods to quantify the effect of antibiotics.

  2007cites this paper
• The Effect of Omeprazole on the Bioavailability and Safety of Garenoxacin in Healthy Volunteers

  2007cites this paper
• Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004).

  2007cites this paper
• Garenoxacin Treatment of Experimental Endocarditis Caused by Viridans Group Streptococci

  2006cites this paper
• Moxifloxacin in the treatment of skin and skin structure infections

  2006cites this paper
• Biology of Pseudomonas stutzeri

  2006cites this paper
• Séparation des énantiomères : innovation thérapeutique et/ou stratégie industrielle ?

  2006cites this paper
• Newer Antistaphylococcal Agents: In-VitroStudies and Emerging Trends in Staphylococcus aureusResistance

  2006cites this paper
• The spectrum of Gram-positive bloodstream infections in patients with hematologic malignancies, and the in vitro activity of various quinolones against Gram-positive bacteria isolated from cancer patients.

  2006cites this paper
• A Review of New Fluoroquinolones

  2006cites this paper
• In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone.

  2005cites this paper
• INTRAVITREAL TOXICITY OF GARENOXACIN

  2005cites this paper
• Selection of Cross-Resistance following Exposure of Pseudomonas aeruginosa Clinical Isolates to Ciprofloxacin or Cefepime

  2005influential citation
• Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae.

  2005cites this paper
• Comparison of the Minimum Inhibitory, Mutant Prevention and Minimum Bactericidal Concentrations of Ciprofloxacin, Levofloxacin and Garenoxacin Against Enteric Gram-negative Urinary Tract Infection Pathogens

  2005cites this paper
• New fluoroquinolones: a class of potent antibiotics.

  2005cites this paper
• Nonfermentative gram-negative bacilli in cancer patients: increasing frequency of infection and antimicrobial susceptibility of clinical isolates to fluoroquinolones.

  2005cites this paper
• parC Mutations in Fluoroquinolone-Resistant Borrelia burgdorferi

  2005cites this paper
• Comparisons of the in vitro susceptibility testing results for garenoxacin using six different national methods: report from the garenoxacin international bridging study.

  2004cites this paper
• In Vitro Activities of Garenoxacin and Levofloxacin against Chlamydia pneumoniae Are Not Affected by Presence of Mycoplasma DNA

  2004cites this paper
• Chemistry and biological activities of 1,8-naphthyridines

  2004cites this paper
• Antimicrobial Activities of Garenoxacin (BMS 284756) against Asia-Pacific Region Clinical Isolates from the SENTRY Program, 1999 to 2001

  2004cites this paper
• Efficacy of Garenoxacin in Treatment of Experimental Endocarditis Due to Staphylococcus aureus or Viridans Group Streptococci

  2004cites this paper
• Population Pharmacokinetics and Pharmacodynamics of Garenoxacin in Patients with Community-Acquired Respiratory Tract Infections

  2004cites this paper
• Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP).

  2004cites this paper
• In Vitro Activities of the Newer Quinolones Garenoxacin, Gatifloxacin, and Gemifloxacin against Human Mycoplasmas

  2004cites this paper
• Gemifloxacin: A New Fluoroquinolone Approved for Treatment of Respiratory Infections

  2004cites this paper
• Wildcatters welcome: the need for new antimicrobial agents

  2004cites this paper
• Comparative in vitro activity of garenoxacin against Cfdamydkz spp

  2004cites this paper
• Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia.

  2003cites this paper
• Re-evaluation of quality control guidelines for gatifloxacin and garenoxacin (BMS284756) when susceptibility testing Haemophilus influenzae and Streptococcus pneumoniae.

  2003cites this paper
• Novel agents for the treatment of resistant Gram-positive infections

  2003cites this paper
• Novel antibacterial agents for the treatment of serious Gram-positive infections

  2003cites this paper
• Accumulation of garenoxacin by Bacteroides fragilis compared with that of five fluoroquinolones.

  2003cites this paper
• Fluoroquinolones in Intensive Care Unit Infections

  2003cites this paper
• Garenoxacin (BMS-284756) and Moxifloxacin in Experimental Meningitis Caused by Vancomycin-Tolerant Pneumococci

  2003cites this paper
• Actividad in vitro comparativa de garenoxacino (BMS-284756). Programa SENTRY España (1999-2000)

  2003influential citation
• Novel antibacterial agents for the treatment of gram positive infections

  2003cites this paper
• Maintaining Fluoroquinolone Class Efficacy: Review of Influencing Factors

  2003cites this paper
• Mechanism of quinolone resistance in anaerobic bacteria.

  2003cites this paper
• Comparaison de l’activité in vitro de la moxifloxacine, de l’ofloxacine, de la ciprofloxacine, de la clindamycine, du métronidazole et de six β-lactamines vis-à-vis des anaérobies stricts

  2003cites this paper
• Pharmacological evaluation of garenoxacin, a novel des-F(6)-quinolone antimicrobial agent: effects on the central nervous system.

  2003cites this paper
• Multiple-Dose Safety and Pharmacokinetics of Oral Garenoxacin in Healthy Subjects

  2003cites this paper
• Postantibiotic Effects of Garenoxacin (BMS-284756) against 12 Gram-Positive or -Negative Organisms

  2003cites this paper
• Influence of patient age on the susceptibility patterns of Streptococcus pneumoniae isolates in North America (2000-2001): report from the SENTRY Antimicrobial Surveillance Program.

  2003cites this paper
• [Comparative in vitro activity of garenoxacin (BMS-284756). Sentry program, Spain (1999-2000)].

  2003cites this paper
• In Vitro Activities of a New Des-Fluoro(6) Quinolone, Garenoxacin, against Clinical Anaerobic Bacteria

  2003cites this paper
• In Vitro Activities of Garenoxacin (BMS-284756) against Streptococcus pneumoniae, Viridans Group Streptococci, and Enterococcus faecalis Compared to Those of Six Other Quinolones

  2003cites this paper